关于参加浙江辖区上市公司 2025 年投资者网上集体接待日活动 暨 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，迪安诊断技术集团股份有限公司（以下 简称"公司"或"迪安诊断"）将参加由浙江证监局指导，浙江上市公司协会主 办，深圳市全景网络有限公司承办的"2025 年浙江辖区上市公司投资者集体接 待日活动暨 2024 年度网上业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 5 月 13 日（周二）15:00-17:00。届时，公 司董事长兼总经理陈海斌、财务负责人赵德康、独立董事李天天、董事会秘书陶 钧（具体参会人员以实际出席为准）将在线就公司 2024 年度业绩、公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等投资者关心的问题， 与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for Q1 2025, attributed to external policy impacts and operational challenges, while also highlighting ongoing efforts to optimize operations and improve cash flow management [1][2][3] Financial Performance - In Q1 2025, the company achieved revenue of 2.365 billion yuan, a year-on-year decrease of 20.45% [1] - The net profit attributable to shareholders was -21 million yuan, a year-on-year decline of 190.66% [1] - The gross profit margin was 26.39%, an increase of 0.87 percentage points year-on-year, while the net profit margin was 0.18%, a decrease of 2.39 percentage points year-on-year [1] Business Segment Analysis - Diagnostic services revenue was 798 million yuan, down 30.55% year-on-year, primarily due to external policy factors [2] - Revenue from channel agency products was 1.576 billion yuan, a decrease of 15.13% year-on-year, impacted by centralized procurement [2] - Self-owned product revenue was 83 million yuan, an increase of 9.21% year-on-year, driven by the growth of specialty products [2] Cash Flow and Receivables Management - As of the end of Q1 2025, accounts receivable and notes totaled 7.477 billion yuan, a decrease of 999.8 million yuan year-on-year [2] - The net operating cash flow was -169 million yuan, an increase of 98 million yuan year-on-year, indicating improved cash flow management [2] Strategic Initiatives - The company is advancing its "digital + automation + AI" business model, forming strategic partnerships with major players like BGI and Ant Group to enhance capabilities in precision medicine and AI applications [3] - The focus on AI and digital transformation positions the company at the forefront of industry innovation [3] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 12.381 billion, 13.117 billion, and 13.935 billion yuan, with expected year-on-year growth rates of 2%, 6%, and 6% respectively [3] - Forecasted net profit attributable to shareholders for the same period is 429 million, 738 million, and 930 million yuan, with growth rates of 220%, 72%, and 26% respectively [3]

Core Insights - The company reported a decline in revenue and net profit for 2024, with total revenue of 12.196 billion yuan, down 9.04% year-on-year, and a net loss of 357 million yuan, down 216.20% year-on-year [1] - The diagnostic services sector showed a high-quality development trend despite a revenue decline, with significant growth in specific areas such as pathogen infection and hematological oncology [2] - The integration of AI in the ICL industry presents new opportunities, with the company achieving notable advancements in AI-driven healthcare solutions [3] - The overall gross margin decreased, while expense ratios remained stable, leading to a net margin decline [4] - Future revenue and profit forecasts indicate a potential recovery from 2025 to 2027, with expected revenue growth and significant increases in net profit [5] Financial Performance - In 2024, the company achieved total revenue of 12.196 billion yuan, a decrease of 9.04% year-on-year, and a net loss of 357 million yuan, a decline of 216.20% year-on-year [1] - The fourth quarter of 2024 saw revenue of 2.938 billion yuan, down 5.71% year-on-year, and a net loss of 488 million yuan, down 118.49% year-on-year [1] - For Q1 2025, revenue was 2.365 billion yuan, a decrease of 20.45% year-on-year, with a net loss of 21 million yuan, down 190.66% year-on-year [1] Business Segments - The diagnostic services business generated revenue of 4.520 billion yuan, down 12.86% year-on-year, with ICL revenue at 4.173 billion yuan, down 11.55% due to cost control policies [2] - The diagnostic products business reported revenue of 8.134 billion yuan, down 6.36% year-on-year, with channel products at 7.787 billion yuan, down 5.99% [2] - Specific areas within diagnostic services, such as pathogen infection, hematological oncology, and neuroimmunology, experienced revenue growth of 57%, 51%, and 38% respectively [2] Strategic Initiatives - The company aims to become a "technology-driven + data-driven" healthcare big data company, leveraging AI to enhance its offerings in the ICL industry [3] - The company has made significant strides in AI, completing the first industry data standard in the pathology AI field and assisting in the interpretation of over 3 million diagnostic reports [3] - The launch of two data element products on the Hangzhou Data Exchange by the end of 2024 indicates progress in data product safety and compliance [3] Profitability Metrics - The overall gross margin for 2024 decreased by 3.28 percentage points to 28.01%, primarily due to industry impacts on diagnostic services [4] - The net margin for 2024 declined by 5.73 percentage points to -1.39% [4] - In Q4 2024, the gross margin was 27.90%, with a net margin of -16.06% [4] Future Outlook - Revenue projections for 2025-2027 are 12.589 billion, 13.201 billion, and 14.114 billion yuan, with year-on-year growth rates of 3%, 5%, and 7% respectively [5] - Expected net profits for the same period are 435 million, 729 million, and 913 million yuan, reflecting growth rates of 222%, 68%, and 25% [5]

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, primarily due to negative impacts from medical anti-corruption policies and increased market competition, but there are signs of gradual recovery in cash flow management and operational efficiency [1][2]. Financial Performance - In 2024, the company achieved operating revenue of 12.196 billion yuan, a year-on-year decrease of 9.04%, and a net profit attributable to shareholders of -357 million yuan, a decline of 216.20% [1]. - The fourth quarter of 2024 saw operating revenue of 2.938 billion yuan, down 5.71% year-on-year, with a net profit of -488 million yuan, a decrease of 118.48% [1]. - The company's gross profit margin was 28.01%, down 3.27 percentage points year-on-year, while the net profit margin was -1.39%, a decline of 5.73 percentage points [2]. Operational Efficiency - The company optimized its operational management, with a sales expense ratio of 9.98%, down 0.33 percentage points, and a management expense ratio of 7.04%, down 0.02 percentage points [2]. - The net cash flow from operating activities in Q4 2024 was 1.153 billion yuan, significantly improved from 333 million yuan in Q3 2024, indicating better management of accounts receivable [2]. Business Segments - The diagnostic services segment generated revenue of 4.520 billion yuan, a decrease of 12.86%, with the ICL business contributing 4.173 billion yuan [3]. - The company focused on high-end specialty testing, with specialty testing revenue of 1.822 billion yuan, accounting for 40.31% of diagnostic services revenue, and significant growth in pathogen infection (57%), hematological oncology (51%), and neuroimmunology (38%) [3]. Product Development - The product business revenue was 8.134 billion yuan, down 6.36%, with self-owned product revenue at 347 million yuan, a decline of 13.90% [4]. - The company is advancing its AI capabilities, having completed the first industry data standard in the pathology AI field and implemented AI solutions in nearly 30 top-tier hospitals [4]. Future Outlook - Revenue projections for 2025-2027 are 12.381 billion yuan, 13.117 billion yuan, and 13.935 billion yuan, with expected growth rates of 2%, 6%, and 6% respectively [5]. - The company anticipates a recovery in the ICL business and improvements in cash flow management, maintaining a buy rating based on the potential for rapid recovery in core business areas and expansion in AI applications [5].

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0344 | 0.0371 | -192.72 | 0.2557 | | 每股净资产（元） | 10.47 | 11.96 | -12.46 | 12.07 | | 每股公积金(元) | 2.93 | 3.01 | -2.66 | 3.05 | | 每股未分配利润(元) | 6.41 | 7.76 | -17.4 | 7.95 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 23.65 | 29.73 | -20.45 | 32.32 | | 净利润(亿元) | -0.21 | 0.23 | -191.3 | 1.6 | | 净资产收益率(%) | -0.32 | 0.31 | -203.23 | 2.14 | 数据四舍五入，查看更多财务数据>> 前十大流通股东累计持有： 11003.92万股，累计占流通股比： 21.95%，较上期 ...

Financial Performance - In Q1 2025, the company reported revenue of CNY 2.37 billion, a decrease of 20.45% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 21 million, representing a decline of 190.66% year-on-year[4] - The net profit after deducting non-recurring gains and losses was a loss of CNY 26 million, down 211.77% from the previous year[4] - Total operating revenue for the current period is ¥2,365,125,686.41, a decrease of approximately 20.4% from ¥2,973,005,617.76 in the previous period[18] - Net profit for the current period is ¥4,172,276.06, a significant decline of 94.5% compared to ¥76,393,132.63 in the previous period[19] - The company reported a loss attributable to the parent company of ¥21,005,565.65, compared to a profit of ¥23,170,466.54 in the previous period[19] Cash Flow and Liquidity - The company's cash flow from operating activities improved by 36.61%, amounting to a net outflow of CNY 169 million[7] - Cash flow from operating activities showed a net outflow of ¥169,216,515.68, an improvement from a net outflow of ¥266,945,833.56 in the previous period[21] - The company's cash and cash equivalents decreased to CNY 1,303,520,270.00 from CNY 1,830,317,273.55, reflecting a decline of approximately 29%[13] - Cash and cash equivalents at the end of the period decreased to ¥1,281,147,970.80 from ¥2,256,555,242.50 in the previous period[22] - Investment activities resulted in a net cash outflow of ¥79,047,843.36, compared to a larger outflow of ¥459,639,091.92 in the previous period[21] - Financing activities generated a net cash outflow of ¥260,482,227.22, contrasting with a net inflow of ¥35,668,498.90 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15.21 billion, a decrease of 3.65% from the end of the previous year[4] - The total assets of the company as of March 31, 2025, amounted to CNY 15,210,416,052.74, a decrease from CNY 15,785,983,734.55 in the previous period[13] - The total liabilities decreased to CNY 6,469,877,512.38 from CNY 7,018,794,162.32, representing a reduction of approximately 7.8%[15] - The company's total equity as of the end of the reporting period was CNY 8,740,538,540.36, down from CNY 8,767,189,572.23, a decrease of about 0.3%[15] - The company's total current assets decreased to CNY 11,358,243,612.83 from CNY 11,902,542,869.23, a decrease of approximately 4.6%[13] Shareholder Information - The company had a total of 54,498 common shareholders at the end of the reporting period[9] - The company held 13,880,000 shares in its repurchase account, accounting for 2.22% of the total share capital at the end of the reporting period[10] Operational Efficiency and Strategy - The company's cash flow from operating activities improved by 36.61%, amounting to a net outflow of CNY 169 million[7] - The gross profit margin increased by approximately 1% year-on-year, indicating improved operational efficiency[8] - The company plans to focus on innovation and operational efficiency, emphasizing a "digital + automation + AI" business model[8] - The company aims to explore new healthcare businesses, including health management, to adapt to complex market conditions[8] Investment and Debt - The investment loss increased by 239.36% due to losses from accounts receivable debt restructuring in subsidiaries[7] - Accounts receivable increased slightly to CNY 7,271,041,135.60 from CNY 7,258,897,680.33, indicating a marginal growth of about 0.17%[13] - Long-term investments increased slightly to CNY 961,108,507.05 from CNY 959,901,876.31, showing a growth of about 0.13%[14] - Short-term borrowings rose to CNY 691,598,078.82 from CNY 616,218,694.22, an increase of approximately 12.2%[15] - The company experienced a credit impairment loss of ¥100,237,182.78, an increase from ¥92,783,263.47 in the previous period[19]

Group 1 - The core point of the announcement is that Dian Diagnostics (300244) reported a significant decline in revenue and a net loss for the first quarter of 2025 [1] Group 2 - The company's operating revenue for Q1 2025 was 2.365 billion yuan, representing a year-on-year decrease of 20.45% [1] - The net loss for the quarter was 21.056 million yuan, compared to a net profit of 23.1705 million yuan in the same period last year [1]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a cautious outlook due to recent performance declines and strategic adjustments [1]. Core Insights - The company reported a revenue of 12.196 billion yuan in 2024, a year-over-year decrease of 9.04%, and a net profit attributable to shareholders of -357 million yuan, reflecting a significant decline of 216.20% year-over-year [1][2]. - The diagnostic services segment generated revenue of 4.520 billion yuan, down 12.86% year-over-year, while the ICL revenue was 4.173 billion yuan, down 11.55% year-over-year. The decline is attributed to cost control measures affecting hospital outsourcing demand [2]. - The company is focusing on enhancing its precision center construction and has seen an increase in the revenue share from tertiary hospitals and specialized testing services, with specialized testing revenue reaching 1.822 billion yuan, accounting for 40.31% of diagnostic services revenue [2]. - The company is experiencing increased competition and impairment losses, which have impacted its apparent profitability. The gross margin decreased by 3.28 percentage points to 28.01% in 2024 [2]. - The company is leveraging AI technology to enhance its diagnostic services, including the launch of the "Di'an Medical Testing Model" in collaboration with Huawei Cloud, aiming to improve diagnostic accuracy and operational efficiency [2]. - Revenue projections for 2025-2027 are estimated at 12.560 billion yuan, 13.189 billion yuan, and 14.016 billion yuan, with corresponding year-over-year growth rates of 3.0%, 5.0%, and 6.3% [2]. Financial Summary - In 2024, the company reported total revenue of 12.196 billion yuan, a decrease of 9.0% from the previous year. The net profit attributable to shareholders was -357 million yuan, a decline of 216.2% year-over-year [4]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.74 yuan, 1.17 yuan, and 1.45 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 18.68, 11.71, and 9.49 [4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a cautious outlook due to recent performance declines and strategic adjustments. Core Viewpoints - The company experienced a revenue decline of 9.04% year-on-year in 2024, with total revenue reaching 12.196 billion yuan and a net loss of 357 million yuan, reflecting a significant drop of 216.20% year-on-year [1][2]. - The diagnostic services segment generated revenue of 4.520 billion yuan, down 12.86% year-on-year, primarily due to reduced demand for outsourced testing services influenced by cost control measures [2]. - The company is focusing on enhancing its precision center construction and has seen an increase in the proportion of revenue from tertiary hospitals and specialized testing services [2]. - The company is leveraging AI technology to drive its digital transformation, aiming to improve operational efficiency and reduce costs [2]. - Future revenue projections indicate a gradual recovery, with expected revenues of 12.560 billion yuan in 2025, growing at a rate of 3.0% year-on-year [4]. Summary by Sections Financial Performance - In 2024, the company reported total revenue of 12.196 billion yuan, a decrease of 9.04% from the previous year, and a net profit attributable to shareholders of -357 million yuan, down 216.20% year-on-year [1][4]. - The gross profit margin decreased to 28.01%, down 3.28 percentage points from the previous year, reflecting increased competition and market challenges [2]. - The company anticipates a recovery in profitability, projecting net profits of 460 million yuan in 2025, representing a growth of 228.8% year-on-year [4]. Business Segments - The diagnostic services business generated 4.520 billion yuan in revenue, with ICL contributing 4.173 billion yuan, both showing declines due to market conditions [2]. - The diagnostic products segment reported revenue of 8.134 billion yuan, with channel products at 7.787 billion yuan and self-produced products at 347 million yuan, indicating a decline influenced by procurement policies and regulatory impacts [2]. Future Outlook - The company is expected to achieve revenues of 131.89 billion yuan in 2026 and 140.16 billion yuan in 2027, with corresponding growth rates of 5.0% and 6.3% respectively [4]. - The strategic focus on AI and digital transformation is anticipated to open new growth avenues and enhance competitive capabilities in the market [2].

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].